Abstract
Protein tyrosine phosphatases (PTPs) are considered to be involved in the etiology of diabetes mellitus, neural diseases such as Alzheimers and Parkinsons disease, regulation of allergy and inflammation, or they are even considered to be responsible for the pathogens` virulence in vivo. Since discovery of first PTP inhibitors such as dephostatin in early 90th years, the research moved on toward search for inhibitors specific for the individual PTP molecules. Currently, dozens of new PTP inhibitors are reported each year, ranging from natural products, natural product analogs, peptides, phosphonates, nonpeptidic inhibitors, mimotopes, metalcontaining inhibitors, redox inhibitors, to simply silencing RNAs as widely used inhibitors of PTP expression. Several currently used drugs also show PTP inhibitory activity. Among them are sodium stibogluconate, phenylarsine oxide, alendronate, etidronate, vanadate, gallium nitrate, suramin, or aplidin. However, the market is still waiting for the first clinically approved selective PTP inhibitor. Here in this review are described inhibitors of activity or expression of the particular classical PTPs, with emphasis on specific inhibition of the respective PTP over the others. The inhibitors are not classified according to their chemical composition, but according to their biological activity, which should help to simplify search for inhibitors of particular classical PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
Keywords: PTP1B, LAR, SHP-1, SHP-2, CD45, protein tyrosine phosphatase inhibition, cancer, diabetes mellitus
Current Medicinal Chemistry
Title: Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs
Volume: 16 Issue: 6
Author(s): P. Heneberg
Affiliation:
Keywords: PTP1B, LAR, SHP-1, SHP-2, CD45, protein tyrosine phosphatase inhibition, cancer, diabetes mellitus
Abstract: Protein tyrosine phosphatases (PTPs) are considered to be involved in the etiology of diabetes mellitus, neural diseases such as Alzheimers and Parkinsons disease, regulation of allergy and inflammation, or they are even considered to be responsible for the pathogens` virulence in vivo. Since discovery of first PTP inhibitors such as dephostatin in early 90th years, the research moved on toward search for inhibitors specific for the individual PTP molecules. Currently, dozens of new PTP inhibitors are reported each year, ranging from natural products, natural product analogs, peptides, phosphonates, nonpeptidic inhibitors, mimotopes, metalcontaining inhibitors, redox inhibitors, to simply silencing RNAs as widely used inhibitors of PTP expression. Several currently used drugs also show PTP inhibitory activity. Among them are sodium stibogluconate, phenylarsine oxide, alendronate, etidronate, vanadate, gallium nitrate, suramin, or aplidin. However, the market is still waiting for the first clinically approved selective PTP inhibitor. Here in this review are described inhibitors of activity or expression of the particular classical PTPs, with emphasis on specific inhibition of the respective PTP over the others. The inhibitors are not classified according to their chemical composition, but according to their biological activity, which should help to simplify search for inhibitors of particular classical PTPs. Even though PTP inhibitors are difficult to develop, lifting the fog of phosphatase inhibition is of the great market potential and further clinical impact.
Export Options
About this article
Cite this article as:
Heneberg P., Use of Protein Tyrosine Phosphatase Inhibitors as Promising Targeted Therapeutic Drugs, Current Medicinal Chemistry 2009; 16 (6) . https://dx.doi.org/10.2174/092986709787458407
DOI https://dx.doi.org/10.2174/092986709787458407 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Endothelial Dysfunction: Novel Therapeutic Approaches (Guest Editor: Dimitris Tousoulis)]
Current Vascular Pharmacology Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives
Current Medicinal Chemistry Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance
Current Medicinal Chemistry Clinical Research on the Aortic Elasticity in Patients with Type 1 Diabetes Mellitus Complicated with Hypertension
Current Medical Imaging Levosimendan Prevents Memory Impairment Induced by Diabetes in Rats: Role of Oxidative Stress
Current Alzheimer Research A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Nitric Oxide and Oral Diseases: Can We Talk About It?
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemistry in the Bioactivity of Chlorophylls: An Overview
Current Medicinal Chemistry Diabetes, Hyperglycemia and Accelerated Atherosclerosis: Evidence Supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Hypoxia and Oxidative Stress in the Causation of Diabetic Retinopathy
Current Diabetes Reviews Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Current Genetic and Epigenetic Insights into Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews Antioxidant Activity, α-glucosidase Inhibitory Activity and Chemoprotective Properties of Rhododendron brachycarpum Leaves Extracts
Current Pharmaceutical Biotechnology Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases
Current Medicinal Chemistry Diabetes and Obesity in Pregnancy: From Patients to Molecular Mechanisms
Current Vascular Pharmacology An Update on Autoinflammatory Diseases
Current Medicinal Chemistry